Quantcast

Latest Antipsychotic Stories

2014-05-14 08:30:09

PITTSBURGH, May 14, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia or the acute treatment of manic or...

2014-05-13 08:33:18

New submission based on positive data from a 15-month schizoaffective relapse prevention study TITUSVILLE, N.J., May 13, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(®) (paliperidone palmitate) to the U.S. Food and Drug Administration (FDA) for approval to treat schizoaffective disorder as either monotherapy or adjunctive...

2014-05-12 16:29:07

-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE, May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the first quarter of 2014, which include: -- 1Q 2014 net loss of $16.6...

2014-05-09 08:26:05

-- Expansion to Approximately 600 Sales Specialists Follows Initiation of National Television Advertising Campaign -- SAN DIEGO, May 9, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales...

2014-05-07 23:14:54

Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name paliperidone, may contribute to an increased risk of leukopenia and neutropenia and gynecomastica according to the FDA. Washington, D.C. (PRWEB) May 07, 2014 Flood Law Group released a statement today announcing that it is now available to investigate potential claims on behalf of people who...

2014-05-07 23:03:04

The Firm is representing Risperdal lawsuit clients who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, NY (PRWEB) May 07, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a group of medical researchers is seeking physician participation in a national registry that tracks the use of atypical antipsychotic medications in pregnant...

2014-05-06 23:10:51

Hundreds of impassioned protesters, including veterans, marched against the American Psychiatric Association which held more than 65 sessions on psychiatric treatment of military personnel, veterans and their families during its annual convention in New York. Citizens Commission on Human Rights launched a petition requesting the U.S. House of Representatives Veterans Affairs Committee to investigate with public hearings the role of psychiatric drugs in veteran suicides, sudden deaths and...

2014-05-06 16:32:22

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning TITUSVILLE, N.J., May 6, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of the company's schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(® )(paliperidone palmitate). The trial found INVEGA(®) SUSTENNA(®) met its primary endpoint of delayed time to and reduced risk of...

2014-05-05 12:29:13

BALTIMORE, May 5, 2014 /PRNewswire/ -- Ameritox(SM), the nation's leader in medication monitoring solutions, introduced Ingenuity Health, a new service providing highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness. http://photos.prnewswire.com/prnvar/20140505/84034 With Ingenuity Health, Ameritox uses urine drug monitoring to address the knowledge gap around medication adherence for the...

2014-05-05 08:29:33

First prospective, randomized clinical trial to reflect context of "real world" issues in treating schizophrenia, including recent incarceration and substance abuse TITUSVILLE, N.J., May 5, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.